The detection of IDH1R132 and IDH2R140/R172 mutations is helpful information to guide the diagnosis of several malignancies such as glioblastomas [4], gliomas [6], AITL [17], MDS [36], or AML [37] and identify patients eligible for anti‐IDH1 and/or anti‐IDH2 targeted therapies. This evidence concerns the gene IDH1 and central nervous system cancer.